Omeros Corporation (OMER) is a biopharmaceutical company which develops and commercialize both small-molecule and protein therapeutics for the treatment of inflammation, coagulopathies and disorders of the central nervous system. Omeros has one of the most diverse pipelines and recently emerged as a strong investment target. The company has one marketed product and four drug candidates in clinical stage with various others in preclinical stage in their pipeline.
